首页> 外文期刊>Food Science and Biotechnology >Control of AMP-activated protein kinase, Akt, and mTOR in EGCG-treated HT-29 colon cancer cells
【24h】

Control of AMP-activated protein kinase, Akt, and mTOR in EGCG-treated HT-29 colon cancer cells

机译:EGCG处理的HT-29结肠癌细胞中AMP激活的蛋白激酶,Akt和mTOR的控制

获取原文
获取原文并翻译 | 示例
           

摘要

Suppressing the mammalian target of rapamycin (mTOR) pathway has emerged as an attractive method for controlling cancer growth and preventing cancers. Epigallocatechin-3-gallate (EGCG) is a well-known chemopreventive polyphenol, and its effects on AMP-activated protein kinase (AMPK) activation were previously reported. In this study the regulatory mechanisms of EGCG on mTOR and Akt, 2 cancer survival signals, and the interrelationships among mTORC1, Akt, and AMPK were examined. It was found that the suppression of mTORC1 by EGCG requires signals from AMPK, however, the inhibition of Akt with EGCG seems to be AMPK independent. Further, there was no clear indication of Akt as an upstream regulator of mTOR in EGCG treated HT-29 colon cancer cells.
机译:抑制雷帕霉素(mTOR)途径的哺乳动物靶点已成为控制癌症生长和预防癌症的一种有吸引力的方法。 Epigallocatechin-3-gallate(EGCG)是一种众所周知的化学预防多酚,其先前对AMP激活的蛋白激酶(AMPK)激活的影响已有报道。在这项研究中,研究了EGCG对mTOR和Akt的调节机制,2种癌症生存信号以及mTORC1,Akt和AMPK之间的相互关系。发现EGCG抑制mTORC1需要来自AMPK的信号,但是,EGCG对Akt的抑制似乎是AMPK独立的。此外,在EGCG治疗的HT-29结肠癌细胞中,没有明确指示Akt作为mTOR的上游调节剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号